Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Support

EnCode-ID project on Intellectual Disabilities receives patronage support from Mutuelles AXA

Published on: 30/11/2023 Reading time: 1 min
Un visage constitué de feuille

An Intellectual Development Disorder (IDD) is a cognitive skills development disorder beginning in early childhood. Despite advances in genetics, in around 50% of cases the cause of this neurodevelopmental disorder is still not identified. The ENCode-ID project, led by Dr. Laïla el-Khattabi within Professor. Bassem Hassan’s team, and in collaboration with the AP-HP/Sorbonne University (Armand Trousseau and Pitié-Salpêtrière hospitals) clinical and biological genetics teams, as well as Lille and Rennes teaching hospitals, has received public health sponsorship support from Mutuelles AXA, as part of the second call for projects launched in February 2023.The aim of ENCode-ID is to identify new genetic causes, severity biomarkers, as well as new therapeutic pathways.

Delayed neurodevelopment can manifest itself in many different ways at an early age, including delayed language development, toilet training, delays in learning to read, etc. When neurodevelopmental milestones are not met at the same age as other children, it is possible that a child may have an Intellectual Development Disorder (IDD). This disorder, which varies in its severity, affects between 1% and 2% of the population. The impact on the child and their family make this a major public health issue.

Genetic diagnosis crucial to treating intellectual developmental disorders

The genetic factors responsible for IDDs are manifold and heterogeneous, making them difficult to

diagnose.Significant technological progress in recent years has substantially increased diagnostic yield, up from 5% a decade ago to 50% today. Although this increase is remarkable, it is still not enough – half of all patients affected by an IDD are still undiagnosed. However, several studies emphasize the positive impact of diagnosis on care, acceptance of the pathology, removing parents’ guilt, and avoiding misdiagnosis.

Genetic diagnosis will therefore be one of the major challenges for intellectual development disorders in the coming years.

Exploring the non-coding genome to improve diagnosis of intellectual development disorders

The ENCode-ID translational medical research project conducted at Paris Brain Instituteby Dr. Laïla El-Khattabi aims to improve IDDs diagnosis rates by exploring the role of genetic variants in non-coding genome sequences. This work should have an immediate impact on patients and their families, particularly for their care and genetic counseling.In addition, the work will generate a considerable amount of data that can be used by the teams at  Paris Brain Institute and by the international community.

Dr Laïla El-Khattabi
Dr Laïla El-Khattabi

ENCode-ID is the first study to propose a comprehensive approach to large-scale functional studies of mutations in non-coding regulatory genomic regions. The project is not just innovative in its approach, but also innovative in the techniques it deploys: multiplex genome editing, use of brain organoids as a model, single cell analysis techniques and innovative bioinformatics tools.

In addition, this is currently the only study to propose in silico exploration of therapeutic pathways for an IDD in a model that closely mimics early brain development in humans, using an algorithm for restoring altered developmental trajectories. This is all made possible through the advanced skills of the lead team, the collaboration with leading clinical teams specializing in this type of disorder, and Paris Brain Institute’s unique expertise and core technological and bioinformatics facilities.

The innovative holistic approach of the encode-id project, supported by Mutuelles Axa's mutual

The ENCode-ID project has successfully secured the support of Mutuelles AXA and will receive healthcare patronage funding over two years, as part of its program dedicated to supporting innovative research initiatives in France.

The healthcare patronage program launched by Mutuelles AXA  in early 2022 is a new commitment that complements its traditional patronage focus areas in support of social, environmental and national heritage causes.

Paris Brain Institute and its teams wish to thank Mutuelles AXA for its continued support.

Our news on the subject

De gauche à droite : Lionel Naccache, Jean Todt, Gérard Saillant et François -Paul Journe
F.P.Journe and Paris Brain Institute celebrate 20 years of partnership with a new collaboration: the RnD Unit F.P.Journe
Paris Brain Institute is proud to be celebrating 20 years of partnership with its first and longest-standing private funder: the watchmaking company F.P.Journe. This partnership, based on shared values of trust, loyalty and excellence, has seen F.P ...
09.17.2024 Support
Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them ...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain ...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol ...
07.16.2024 Research, science & health
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)
In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and ...
06.28.2024 Research, science & health
Une tête de statue de l'île de Pâques sur laquelle sont posées des éléctrodes
A multimodal approach to better predict recovery in patients with disorders of consciousness
When a patient is admitted to intensive care due to a disorder of consciousness—such as a coma—establishing their neurological prognosis is a crucial yet challenging task. To reduce the uncertainty that precedes the medical decision, a group of ...
05.30.2024 Research, science & health
See all our news